Healthcare & Pharmaceutical Market Research in the USA

BioNixus is a leading healthcare market research company in the USA, delivering IRB-compliant HCP surveys, KOL mapping, and payer landscape research aligned with FDA, CMS, and PBM requirements. BioNixus combines primary research depth with physician access across major US academic medical centres and specialist community networks.

A healthcare market research company in the USA designs and executes studies covering physician prescribing behavior, payer and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the US market.

The US is uniquely decentralized: FDA approval does not guarantee market access. Commercial outcomes depend on PBM formulary placement (UnitedHealth/Optum, CVS/Caremark, Express Scripts), Medicare Part B/D CMS coverage decisions, and hospital GPO and P&T committee listings — each with distinct evidence requirements. IRA Medicare price negotiation (effective 2026) has added further strategic complexity for products with significant Medicare exposure.

BioNixus covers oncology, immunology and biologics, cardiovascular, diabetes and metabolic (including GLP-1/IRA dynamics), rare disease and gene therapy, respiratory, infectious disease, neurology, and consumer health across the US market.

Yes. BioNixus maintains physician and specialist networks across major US academic medical centres (Mayo Clinic, Cleveland Clinic, Johns Hopkins, UCSF, MSKCC, MGH) and community IDN networks. For scarce specialties such as oncology or rare disease, we recruit through NCI cancer centre networks and rare disease specialist directories.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, IRB review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-AMC recruitment may require extended planning timelines.

Yes. BioNixus designs and executes US patient research in compliance with HIPAA/HITECH data privacy standards and IRB/OHRP ethics requirements under 45 CFR Part 46. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling.

Yes. US modules can run with comparable cells in the UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.